Resistance to Afatinib and Cetuximab Combination Therapy in EGFR-mutant Lung Adenocarcinomas

被引：0
|
作者：
Pirazzoli, Valentina
Takezawa, Ken
de Stanchina, Elisa
Pao, William
Politi, Katerina
机构：
来源：
CLINICAL CANCER RESEARCH | 2012年 / 18卷 / 10期
关键词：
D O I：
10.1158/1078-0432.MECHRES-A38
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A38
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
    Lee, Jiyun
    Piotrowska, Zofia
    Soo, Ross
    Cho, Byoung Chul
    Lim, Sun Min
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [32] APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas
    Selenica, P.
    Marra, A.
    Choudhury, N. J.
    Gazzo, A.
    Falcon, C. J.
    Patel, J.
    Pei, X.
    Zhu, Y.
    Ng, C. K. Y.
    Curry, M.
    Heller, G.
    Zhang, Y. -K.
    Berger, M. F.
    Ladanyi, M.
    Rudin, C. M.
    Chandarlapaty, S.
    Lovly, C. M.
    Reis-Filho, J. S.
    Yu, H. A.
    ANNALS OF ONCOLOGY, 2022, 33 (12) : 1284 - 1295
  • [33] Clinicopathologic and molecular characteristics of EGFR-mutant lung adenocarcinomas that transform to small-cell lung cancer after TKI therapy
    Yu, Li
    Bazhenova, Lyudmila
    Gold, Kathryn
    Tran, Lisa
    Hilburn, Van
    Vu, Peter
    Patel, Sandip Pravin
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (03) : 452 - 461
  • [34] Mechanism exploration and model construction for small cell transformation in EGFR-mutant lung adenocarcinomas
    Li, Yan
    Xie, Tongji
    Wang, Shouzheng
    Yang, Lin
    Hao, Xuezhi
    Wang, Yan
    Hu, Xingsheng
    Wang, Lin
    Li, Junling
    Ying, Jianming
    Xing, Puyuan
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [35] Enhancing apoptosis to improve the therapy of EGFR-mutant lung cancer
    Tanaka, Kosuke
    Han, Song
    Ganesan, Yogesh T.
    Hsieh, James J.
    Cheng, Emily H.
    CANCER RESEARCH, 2019, 79 (13)
  • [36] Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial
    Yonesaka, Kimio
    Hayashi, Hidetoshi
    Nakamura, Atsushi
    Sato, Yuki
    Azuma, Koichi
    Sakata, Shinya
    Tachihara, Motoko
    Ikeda, Satoshi
    Yokoyama, Toshihide
    Ito, Kentaro
    Yano, Yukihiro
    Matsumoto, Hirotaka
    Daga, Haruko
    Hata, Akito
    Sakai, Kazuko
    Chiba, Yasutaka
    Nishio, Kazuto
    Yamamoto, Nobuyuki
    Nakagawa, Kazuhiko
    CLINICAL LUNG CANCER, 2023, 24 (06) : 519 - +
  • [37] Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors
    Landi, Lorenza
    Tiseo, Marcello
    Chiari, Rita
    Ricciardi, Serena
    Rossi, Elisa
    Galetta, Domenico
    Novello, Silvia
    Milella, Michele
    D'Incecco, Armida
    Minuti, Gabriele
    Tibaldi, Carmelo
    Salvini, Jessica
    Facchinetti, Francesco
    Haspinger, Eva Regina
    Cortinovis, Diego
    Santo, Antonio
    Banna, Giuseppe
    Catino, Annamaria
    GiajLevra, Matteo
    Crino, Lucio
    de Marinis, Filippo
    Cappuzzo, Federico
    CLINICAL LUNG CANCER, 2014, 15 (06) : 411 - 417
  • [38] Afatinib with or without Cetuximab for First-Line Treatment of EGFR-Mutant NSCLC: Interim Safety Results of SWOG 51403
    Goldberg, Sarah
    Moon, James
    Lilenbaum, Rogerio
    Politi, Katerina
    Melnick, Mary Ann
    Stinchcombe, Thomas
    Horn, Leora
    Chen, Everett
    Miao, Jieling
    Redman, Mary
    Kelly, Karen
    Gandara, David R.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1220 - S1221
  • [39] Longitudinal Analysis of Plasma CtDNA in EGFR-Mutant NSCLC: SWOG S1403 Trial of Afatinib with or Without Cetuximab
    Mack, P.
    Miao, J.
    Banks, K.
    Burich, R.
    Politi, K.
    Raymond, V.
    Dix, D.
    Lanman, R.
    Moon, J.
    Melnick, M. A.
    Truini, A.
    Redman, M.
    Goldberg, S.
    Gandara, D. R.
    Kelly, K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2219 - S2219
  • [40] Real-world Experience of the Utility in Afatinib Therapy for Patients with EGFR-Mutant Advanced NSCLC
    Igawa, S.
    Ono, T.
    Kasajima, M.
    Yamada, K.
    Oguri, A.
    Kameda, A.
    Yamamoto, H.
    Kakegawa, M.
    Hiyoshi, Y.
    Kusuhara, S.
    Ozawa, T.
    Otani, S.
    Fukui, T.
    Mitsufuji, H.
    Masaru, K.
    Yokoba, M.
    Kubota, M.
    Sasaki, J.
    Naoki, K.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S611 - S611
12345